SCHEMBL2852193

SCHEMBL2852193

C[Si](C)(C)n1cc(F)c(N)nc1=O

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.40
DCK P27707 5/20 0.33
EP300 Q09472 1/20 0.32
POLG P54098 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033158 0.78
SCHEMBL9124228 0.77
SCHEMBL1225898 0.76 ALB (0.38) ALBDCKEP300
SCHEMBL1739594 0.74 ALB (0.38) ALBDCKEP300POLG
SCHEMBL28349363 0.74 ALB (0.39) ALBDCKEP300POLG
SCHEMBL17041816 0.74 ALB (0.39) ALBDCKEP300POLG
SCHEMBL27757661 0.72 ALB (0.38) ALBDCKEP300POLG
SCHEMBL18080744 0.72 ALB (0.41) ALBDCKEP300POLG
SCHEMBL18665254 0.72 ALB (0.38) ALBDCKEP300POLG
SCHEMBL27819800 0.72 ALB (0.38) ALBDCKEP300POLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130734-A1 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-05-27 US claimed
EP-2137201-A2 PROCESS FOR PREPARING CAPECITABINE Dr. Reddy's Laboratories Ltd. (IN) 2009-12-30 EP claimed
WO-2008131062-A2 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2008-10-30 WO claimed
CN-1646141-B Modified nucleosides for treating viral infections and abnormal cell proliferation PHARMASSET LTD 2014-06-25 CN disclosed
CN-101862345-B Modified nucleosides for treatment of viral infections and abnormal cellular proliferation GILEAD SCIENCES INC 2014-06-04 CN disclosed
CN-101862345-A The modified nucleosides that is used for the treatment of viral infection and abnormal cell proliferation PHARMASSET LTD 2010-10-20 CN disclosed
US-20100130734-A1 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-05-27 US disclosed
EP-2164856-A1 PROCESSES RELATED TO MAKING CAPECITABINE Synthon B.V. (NL) 2010-03-24 EP disclosed
EP-2137201-A2 PROCESS FOR PREPARING CAPECITABINE Dr. Reddy's Laboratories Ltd. (IN) 2009-12-30 EP disclosed
US-20080300399-A1 PROCESSES RELATED TO MAKING CAPECITABINE SYNTHON BV (NL) 2008-12-04 US disclosed
WO-2008145403-A1 PROCESSES RELATED TO MAKING CAPECITABINE SYNTHON B.V. (NL) 2008-12-04 WO disclosed
WO-2008131062-A2 PROCESS FOR PREPARING CAPECITABINE DR. REDDY'S LABORATORIES LTD. (IN) 2008-10-30 WO disclosed
CN-1646141-A Modified nucleosides for treating viral infections and abnormal cell proliferation PHARMASSET LTD (BB) 2005-07-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130734-A1 PROCESS FOR PREPARING CAPECITABINE DPYD, TYMP, TYMS ALB 1169/4885DCK 23/4885EP300 4205/4885
US-20080300399-A1 PROCESSES RELATED TO MAKING CAPECITABINE DPYD, TYMP, TPMT ALB 811/4885DCK 29/4885EP300 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.